Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ESPR
DateTimeSourceHeadlineSymbolCompany
22/05/202413:00GlobeNewswire Inc.First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular RiskNASDAQ:ESPREsperion Therapeutics Inc
20/05/202421:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
20/05/202411:00GlobeNewswire Inc.Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for HypercholesterolemiaNASDAQ:ESPREsperion Therapeutics Inc
17/05/202420:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
14/05/202413:00GlobeNewswire Inc.Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®NASDAQ:ESPREsperion Therapeutics Inc
10/05/202421:00GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
08/05/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
07/05/202413:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
07/05/202412:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
07/05/202411:00GlobeNewswire Inc.Esperion Reports First Quarter 2024 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
29/04/202413:00GlobeNewswire Inc.Esperion to Participate in Upcoming May Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
23/04/202413:00GlobeNewswire Inc.Esperion to Report First Quarter 2024 Financial Results on May 7NASDAQ:ESPREsperion Therapeutics Inc
07/04/202419:45GlobeNewswire Inc.Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityNASDAQ:ESPREsperion Therapeutics Inc
01/04/202413:00GlobeNewswire Inc.Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024NASDAQ:ESPREsperion Therapeutics Inc
26/03/202412:00GlobeNewswire Inc.Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
25/03/202420:00GlobeNewswire Inc.Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24NASDAQ:ESPREsperion Therapeutics Inc
22/03/202422:26Business WireU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202419:10GlobeNewswire Inc.U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202415:04GlobeNewswire Inc.CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsNASDAQ:ESPREsperion Therapeutics Inc
27/02/202414:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ESPREsperion Therapeutics Inc
27/02/202412:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
27/02/202411:00GlobeNewswire Inc.Esperion Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
16/02/202421:30GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
14/02/202419:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
14/02/202415:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
14/02/202413:42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
14/02/202411:11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
13/02/202413:00GlobeNewswire Inc.Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27NASDAQ:ESPREsperion Therapeutics Inc
01/02/202419:00GlobeNewswire Inc.RFK, Esperion Therapeutics Announce 2024 Promotional ScheduleNASDAQ:ESPREsperion Therapeutics Inc
23/01/202421:00GlobeNewswire Inc.Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesNASDAQ:ESPREsperion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ESPR

Your Recent History

Delayed Upgrade Clock